ArticleFASEB bioAdvances2025
Ogerin induced activation of Gpr68 alters tendon healing.
Article in FASEB bioAdvances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ogerin induced activation of Gpr68 alters tendon healing.FASEB bioAdvances · 2025Article
- Single-cell sequencing reveals cellular heterogeneity and molecular mechanisms in tendon and enthesis injury repair.Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Satisfactory outcomes after acute tendon injuries are hampered by a fibrotic healing response. As such, modulation of extracellular matrix deposition and remodeling represents an important intervention point to improve healing. During fibrosis, matrix is deposited and remodeled by activated fibroblasts and/or myofibroblasts. Recent work has demonstrated that Ogerin, a positive allosteric modulator of the orphan proton-sensing GPCR, GPR68, can modulate fibroblast ↔ myofibroblast dynamics in multiple fibroblast populations, including blunting myofibroblast differentiation and facilitating reversion of mature myofibroblasts to a basal fibroblast state in vitro. In the present study, we tested the ability of Ogerin to modulate tendon fibroblast ↔ myofibroblast behavior in vitro and in vivo. Consistent with prior work, Ogerin can both blunt TGF-β induced tenocyte → myofibroblast differentiation and partially revert mature myofibroblasts to a basal tenocyte state. However, Ogerin treatment from days 8-12 after tendon repair surgery did not inhibit myofibroblast differentiation, and Ogerin treatment from post-operative days 24-28 did not induce myofibroblast reversion. Moreover, while we expected Ogerin treatment from days 8-12 to impair healing due to blunted extracellular matrix formation, Ogerin treatment improved tendon mechanical properties and altered cell transcriptional profiles and communication patterns in a way that suggests accelerated remodeling and resolution of the repair response, identifying Ogerin as a novel therapeutic approach to improve the tendon healing process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.